ArticleMicrosystems & nanoengineering2022
Integrated microfluidic single-cell immunoblotting chip enables high-throughput isolation, enrichment and direct protein analysis of circulating tumor cells.
Article in Microsystems & nanoengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Circulating tumour cells for guiding antibody‒drug conjugate therapy: Role of artificial intelligence.Clinical and translational medicine · 2026Review
- Recent advances in integrated biophysical and biochemical microfluidic methods for circulating tumor cells isolation and analysis.Fundamental research · 2026Review
- A 3D modeling framework for accurate trajectory-based prediction of critical diameter in deterministic lateral displacement microfluidics.Microsystems & nanoengineering · 2026Article
- ASM-chip: an antibody-modified size-screening microfluidic chip for high-efficiency circulating glioma cell isolation and clinical application.Microsystems & nanoengineering · 2026Article
- From microfluidics to nanodelivery: artificial intelligence reshapes neuropharmacology research strategies.Frontiers in pharmacology · 2026Review
- High-throughput cancer cell isolation via dynamic anti-clogging microsieve filtration.Frontiers in bioengineering and biotechnology · 2026Article
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- Advances in microfluidic chip technology for cell analysis.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Unlocking the Potential of Liquid Biopsy: A Paradigm Shift in Endometrial Cancer Care.Diagnostics (Basel, Switzerland) · 2025Review
- Isolation Techniques of Micro/Nano-Scaled Species for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Modeling the dynamics of circulating tumor cell clusters inside a microfluidic channel.Biomicrofluidics · 2025Article
- Digital Quantitative Detection for Heterogeneous Protein and mRNA Expression Patterns in Circulating Tumor Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mapping Nanoscale-To-Single-Cell Phosphoproteomic Landscape by Chip-DIA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Miniaturized protein profiling permits targeted signaling pathway analysis in individual circulating tumor cells to improve personalized treatment.Journal of translational medicine · 2024Article
- A mini review on recent progress of microfluidic systems for antibody development.Journal of diabetes and metabolic disorders · 2024Review
- Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.International journal of molecular sciences · 2024Review
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- Integrated Microfluidics for Single-Cell Separation and On-Chip Analysis: Novel Applications and Recent Advances.Small science · 2024Article
- Microfluidic design in single-cell sequencing and application to cancer precision medicine.Cell reports methods · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective capture and analysis of a single circulating tumor cell (CTC) is instrumental for early diagnosis and personalized therapy of tumors. However, due to their extremely low abundance and susceptibility to interference from other cells, high-throughput isolation, enrichment, and single-cell-level functional protein analysis of CTCs within one integrated system remains a major challenge. Herein, we present an integrated multifunctional microfluidic system for highly efficient and label-free CTC isolation, CTC enrichment, and single-cell immunoblotting (ieSCI). The ieSCI-chip is a multilayer microfluidic system that combines an inertia force-based cell sorter with a membrane filter for label-free CTC separation and enrichment and a thin layer of a photoactive polyacrylamide gel with microwell arrays at the bottom of the chamber for single-cell immunoblotting. The ieSCI-chip successfully identified a subgroup of apoptosis-negative (Bax-negative) cells, which traditional bulk analysis did not detect, from cisplatin-treated cells. Furthermore, we demonstrated the clinical application of the ieSCI-chip with blood samples from breast cancer patients for personalized CTC epithelial-to-mesenchymal transition (EMT) analysis. The expression level of a tumor cell marker (EpCAM) can be directly determined in isolated CTCs at the single-cell level, and the therapeutic response to anticancer drugs can be simultaneously monitored. Therefore, the ieSCI-chip provides a promising clinical translational tool for clinical drug response monitoring and personalized regimen development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.